GlycoVaxyn and GlaxoSmithKline Biologicals(GSK)have signed a research partnership for the development of new bacterial vaccines.
The collaboration,planned for three years,will leverage GlycoVaxyn's bio-conjugation technology in developing vaccines against a range of undisclosed bacterial pathogens.
GlycoVaxyn co-founder and chief scientific officer Michael Wacker said,"GlycoVaxyn's technology is designed to enable or improve the development of anti-bacterial conjugate vaccines by in vivo synthesis of protein-polysaccharide complexes in E.coli,via recombinant DNA technology."
As per the deal,GlycoVaxyn will obtain an upfront payment along with an equity investment in addition to milestone payments and royalties on licensed candidates.
During the collaboration,GSK has an option to acquire exclusive license on the vaccine targets,extend the period of collaboration and expand the capacity of the partnership.
GlycoVaxyn chief executive officer Philippe Dro said,"We are looking forward to working with GlaxoSmithKline Biologicals to develop and bring to market important new vaccines that have the potential to save or change the lives of millions of people."
Financial terms of the deal were not revealed.
